{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:26:49Z","timestamp":1791646009996,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jconrel.2022.11.043","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T18:31:34Z","timestamp":1671647494000},"page":"1023-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Pulmonary drug delivery technology enables anakinra repurposing in cystic fibrosis"],"prefix":"10.1016","volume":"353","author":[{"given":"Matteo","family":"Puccetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Pariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stincardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Wojtylo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Schoubben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Nunzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Giovagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.11.043_bb0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ncb1456","article-title":"CFTR regulates phagosome acidification in macrophages and alters bactericidal activity","volume":"8","author":"Di","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0010","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.1021\/bi060490t","article-title":"CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis","volume":"45","author":"Painter","year":"2006","journal-title":"Biochemistry."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0015","first-page":"L383","article-title":"CFTR inhibition mimics the cystic fibrosis inflammatory profile","volume":"292","author":"Perez","year":"2007","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic fibrosis foundation pulmonary guidelines. Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112717","article-title":"Selectively targeting key inflammatory pathways in cystic fibrosis","volume":"206","author":"Costantini","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"Suppl. 3","key":"10.1016\/j.jconrel.2022.11.043_bb0035","first-page":"S5","article-title":"Mucus obstruction and inflammation in early cystic fibrosis lung disease: emerging role of the IL-1 signaling pathway","volume":"54","author":"Bal\u00e1zs","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0040","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1172\/JCI125669","article-title":"IL-1\u03b2 dominates the promucin secretory cytokine profile in cystic fibrosis","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0045","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1164\/rccm.201409-1610OC","article-title":"Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease","volume":"191","author":"Fritzsching","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.jconrel.2022.11.043_bb0050","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.3390\/ijms22126531","article-title":"Anakinra activates superoxide dismutase 2 to mitigate Inflammasome activity","volume":"22","author":"Pariano","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0055","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1038\/ncomms10791","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis","volume":"7","author":"Iannitti","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2022.11.043_bb0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144983","article-title":"Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagy","volume":"132","author":"van de Veerdonk","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","article-title":"Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations","volume":"32","author":"Kaiser","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s43556-020-00014-z","article-title":"Developing inhaled protein therapeutics for lung diseases","volume":"1","author":"Matthews","year":"2020","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0075","series-title":"Kineret: Product Information","author":"European Medicines Agency","year":"2022"},{"key":"10.1016\/j.jconrel.2022.11.043_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.02.014","article-title":"Prospects of formulating proteins\/peptides as aerosols for pulmonary drug delivery","volume":"314","author":"Shoyele","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0378-5173(95)04209-1","article-title":"Protein nebulization. 2. Stabilization of G-CSF to air-jet nebulization and the role of protectants","volume":"127","author":"Niven","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0378-5173(03)00126-1","article-title":"The effect of formulation variables on the stability of nebulized aviscumine","volume":"257","author":"Steckel","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0095","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/pharmaceutics12111025","article-title":"Pulmonary delivery of biological drugs","volume":"12","author":"Liang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2022.11.043_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2013.11.013","article-title":"Alternative carriers in dry powder inhaler formulations","volume":"19","author":"Rahimpour","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.11.043_bb0105","article-title":"Inhaled mannitol for cystic fibrosis","volume":"2020","author":"Nevitt","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cocis.2021.101497","article-title":"Natural and bioinspired excipients for dry powder inhalation formulations","volume":"56","author":"Zillen","year":"2021","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.powtec.2021.03.021","article-title":"Approaches for improving the flowability of high-protein dairy powders post spray drying \u2013 a review","volume":"388","author":"Hazlett","year":"2021","journal-title":"Powder Technol."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jfoodeng.2015.11.010","article-title":"Solvent-free production of protein-enriched fractions from navy bean flour using a triboelectrification-based approach","volume":"174","author":"Tabtabaei","year":"2016","journal-title":"J. Food Eng."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0125","first-page":"42","article-title":"Probing thermal stability of MAbs by intrinsic tryptophan fluorescence a practical approach for preformulation development","volume":"June 1","author":"Weichel","year":"2008","journal-title":"BioProcess Int."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109871","article-title":"Oligomerization, conformational stability and thermal unfolding of Harpin, HrpZPss and its hypersensitive response-inducing c-terminal fragment, C-214-HrpZPss","volume":"9","author":"Tarafdar","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.11.043_bb0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1248\/cpb.42.5","article-title":"Effect of mannitol crystallinity on the stabilization of enzymes during freeze-drying","volume":"42","author":"Izutsu","year":"1994","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.jconrel.2022.11.043_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121974","article-title":"Mannitol hemihydrate in lyophilized protein formulations: impact of its dehydration during storage on sucrose crystallinity and protein stability","volume":"624","author":"Sonje","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ejpb.2008.02.010","article-title":"Stabilization of IgG1 in spray-dried powders for inhalation","volume":"69","author":"Sch\u00fcle","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118724","article-title":"Amino acids as stabilizers for spray-dried simvastatin powder for inhalation","volume":"572","author":"Lu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpb.2015.04.035","article-title":"Relationship between surface concentration of l-leucine and bulk powder properties in spray dried formulations","volume":"94","author":"Mangal","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijpharm.2009.08.007","article-title":"Influence of protein on mannitol polymorphic form produced during co-spray drying","volume":"382","author":"Hulse","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0165","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1021\/js9800679","article-title":"Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody","volume":"87","author":"Costantino","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0170","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1526-0550(02)00003-3","article-title":"Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and persistence","volume":"3","author":"Davies","year":"2002","journal-title":"Paediatr. Respir. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2022.11.043_bb0175","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1164\/rccm.201305-0986OC","article-title":"Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis","volume":"188","author":"Iannitti","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.043_bb0180","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/1753425917698032","article-title":"Hypoxia and the hypoxia-regulated transcription factor HIF-1\u03b1 suppress the host defence of airway epithelial cells","volume":"23","author":"Polke","year":"2017","journal-title":"Innate Immun."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0185","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0882-4010(87)90007-6","article-title":"Purified human and recombinant murine interleukin-1 alpha induced accumulation of inflammatory peritoneal neutrophils and mononuclear phagocytes: possible contributions to antibacterial resistance","volume":"3","author":"Czuprynski","year":"1987","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0190","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","article-title":"Anakinra for the treatment of rheumatoid arthritis: a safety evaluation","volume":"17","author":"Ram\u00edrez","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0195","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fphar.2019.00148","article-title":"Corrigendum: Anakinra therapy for non-cancer inflammatory diseases","volume":"10","author":"Cavalli","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11095-021-03146-1","article-title":"Uniformity and efficacy of dry powders delivered to the lungs of a mycobacterial-surrogate rat model of tuberculosis","volume":"39","author":"Hirota","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0205","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ijpharm.2012.05.013","article-title":"Pulmonary delivery of dry powders to rats: tolerability limits of an intra-tracheal administration model","volume":"434","author":"Guillona","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.119.257311","article-title":"Translation of inhaled drug optimization strategies into clinical pharmacokinetics and pharmacodynamics using GSK2292767A, a novel inhaled phosphoinositide 3-kinase d inhibitor","volume":"369","author":"Begg","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128627","article-title":"Medicinal chemistry strategies to extend duration of action of inhaled drugs for intracellular targets","volume":"62","author":"Samy","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.043_bb0220","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using pulmosphereTM technology","volume":"24","author":"Geller","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.11.043_bb0225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200788X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200788X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:43:38Z","timestamp":1759164218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592200788X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":45,"alternative-id":["S016836592200788X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.043","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary drug delivery technology enables anakinra repurposing in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}